Skip to main content
Fig. 5 | Breast Cancer Research

Fig. 5

From: Cetuximab PET delineated changes in cellular distribution of EGFR upon dasatinib treatment in triple negative breast cancer

Fig. 5

Dasatinib (Das) and cetuximab (Cet) combinatorial treatment after [89Zr]Zr-cetuximab PET. The treatment and imaging scheme for tumor-bearing mice employed initial dosing of dasatinib (50 mg/kg, 5×/week, p.o.) or vehicle (UnTx) for 5 days followed by PET imaging on day 7. The mice were then separated into three groups, keeping the vehicle-treated mice till day 28. The other cohorts were continued for treatment with dasatinib alone or in combination with cetuximab (0.2 mg i.p. 2×/week) (a). The tumor growth rates were compared using linear mixed-effects models on log-transformed data, and the p values were adjusted for multiplicity using Holm’s procedure in MDA-MB-231 (b) and MDA-MB-468 (c) xenografts. Asterisks indicate significant differences, and the error bars represent 95% confidence intervals. A plot of the tracer uptake vs. %Δ tumor volumes of MDA-MB-468 tumors exhibited a direct correlation with higher PET tracer uptake corresponding to higher tumor regression (d)

Back to article page